Business · 10/10/2002Updated: 10/17/2026 · 1 min read
Lilly Research Labs et al.; FDA Withdraws Approval of 16 New Drug Applications and 30 Abbreviated New Drug Applications
Summary
The US Food and Drug Administration (FDA) has withdrawn approval of 16 new drug applications (NDAs) and 30 abbreviated new drug applications (ANDAs) following written notifications from the applicants that the corresponding drug products are no longer commercially available.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →